October 27, 2017 — iCAD Inc. announced that its PowerLook Tomo Detection has been named 2017 Product of the Year by the New Hampshire High Technology Council, a member-driven organization with a focus on advancing innovation throughout the State of New Hampshire. Built on deep learning (artificial intelligence) technology, PowerLook Tomo Detection is the first and only concurrent-read cancer detection solution for digital breast tomosynthesis (DBT), according to the company, engineered to make it possible for radiologists to detect breast cancer more efficiently.
“With a 29.2 percent average reduction in radiologist reading time and over 92 percent of malignant soft tissue densities detected, PowerLook Tomo Detection’s advanced technology is dramatically improving both workflow and image interpretation,” said Ken Ferry, CEO of iCAD. “This prestigious award underscores not only iCAD’s innovation, but also the promising future of advanced early breast cancer detection.”
One of the premier business events in New Hampshire, the 2017 Product of the Year competition marks the 12th year that the New Hampshire High Tech Council has highlighted local innovators. During the event, each of the product finalists made a final, seven-minute pitch about their recently developed product. Following the presentations, audience members cast their votes for the top product, and iCAD was awarded Product of the Year.
The PowerLook Tomo Detection solution rapidly scans each plane in the tomosynthesis, or high-resolution 3-D image, volume to identify suspicious soft tissue densities, including masses, architectural distortions and asymmetries. These soft tissue densities are extracted from the planes and naturally blended onto a synthetic 2-D mammography image, creating an efficient and effective navigation tool for radiologists to decrease reading time and improve reader experience.
Unlike traditional 2-D mammography cancer detection solutions, PowerLook Tomo Detection is designed to be used concurrently throughout study interpretation. The solution was approved for clinical use by the U.S. Food and Drug Administration (FDA) in March 2017, and is currently the only FDA-approved tomosynthesis cancer computer-aided detection solution available in the U.S.
For more information: www.icadmed.com
July 16, 2026 
